Pharmacy Medical Necessity Guidelines: Sirturo™ (bedaquiline)

Effective: August 08, 2017

<table>
<thead>
<tr>
<th>Prior Authorization Required</th>
<th>✓</th>
<th>Type of Review – Care Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Covered</td>
<td></td>
<td>Type of Review – Clinical Review</td>
</tr>
<tr>
<td>Pharmacy (RX) or Medical (MED) Benefit</td>
<td>RX</td>
<td>Department to Review</td>
</tr>
</tbody>
</table>

This Pharmacy Medical Necessity Guideline applies to the following:

**Tufts Health Plan Commercial Plans**
- ✓ Tufts Health Plan Commercial Plans – large group plans
- ✓ Tufts Health Plan Commercial Plans – small group and individual plans

**Tufts Health Public Plans**
- ✓ Tufts Health Direct – Health Connector
- ✓ Tufts Health Together – A MassHealth Plan
- ✓ Tufts Health RITogether – A Rite Care + Rhody Health Partners Plan

**Tufts Health Freedom Plan products**
- ✓ Tufts Health Freedom Plan – large group plans
- ✓ Tufts Health Freedom Plan – small group plans

**Fax Numbers:**
- RXUM: 617.673.0988

**Note:** For Tufts Health Plan Medicare Preferred Members, please refer to the Tufts Health Plan Medicare Preferred Prior Authorization Criteria. Background, applicable product and disclaimer information can be found on the last page.

**OVERVIEW**

**FDA-APPROVED INDICATIONS**

Sirturo (bedaquiline) is indicated as part of combination therapy in adult patients (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Sirturo should be reserved for use when an effective treatment regimen cannot otherwise be provided.

World Health Organization (WHO) guidelines for the management of MDR-TB recommend that treatment regimens should be based on the history of drugs taken by the patients, taking into account the drugs and regimens commonly used in the country and the prevalence of resistance to first-line and second-line drugs. Drug regimens should consist of at least five drugs. Often, more than four drugs may be started if the susceptibility pattern is unknown, if effectiveness is questionable or if extensive, bilateral, pulmonary disease is present.

Sirturo should be administered under directly observed therapy (DOT). Sirturo should only be used in combination with at least three other drugs to which the patient’s MDR-TB isolate has been shown to be susceptible in vitro. If in vitro testing results are unavailable, treatment may be initiated with Sirturo in combination with at least four other drugs to which the patient’s MDR-TB isolate is likely to be susceptible.

**COVERAGE GUIDELINES**

The plan may authorize coverage of Sirturo (bedaquiline) for Members when **ALL** of the following criteria are met:

1. Documented diagnosis of pulmonary multi-drug resistant tuberculosis

   AND

2. The Member is at least 18 years of age

   AND

3. Sirturo should only be used in combination with at least three other drugs to which the patient’s MDR-TB isolate has been shown to be susceptible in vitro. If in vitro testing results are unavailable, treatment may be initiated with Sirturo in combination with at least four other drugs to which the patient’s MDR-TB isolate is likely to be susceptible.

**LIMITATIONS**

None

**CODES**

None
REFERENCES

APPROVAL HISTORY
July 9, 2013: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:
- August 12, 2014: No changes.
BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. They are used in conjunction with a Member’s benefit document and in coordination with the Member’s physician(s). The plan makes coverage decisions on a case-by-case basis considering the individual Member’s health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

This Pharmacy Medical Necessity Guideline does not apply to Uniformed Services Family Health Plan Members or to certain delegated service arrangements. Unless otherwise noted in the Member’s benefit document or applicable Pharmacy Medical Necessity Guideline, Pharmacy Medical Necessity Guidelines do not apply to CareLink℠ Members. For self-insured plans, drug coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a coverage guideline and a self-insured Member’s benefit document, the provisions of the benefit document will govern. Applicable state or federal mandates will take precedence.

For Tufts Health Plan Medicare Preferred, please refer to Tufts Health Plan Medicare Preferred Prior Authorization Criteria.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to Member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.